Table 2.

Characteristics of Patients at Week 24

Total (n = 94)Group A (n = 51)Group B (n = 43)P
(Group A vs Group B)
HBsAg, log10 IU/mL3.7 ± 0.63.7 ± 0.63.6 ± 0.7.2285
HBeAg, log10 PEIU/mL2.0 ± 1.01.9 ± 1.02.1 ± 0.9.2121
HBV DNA, log 10 cps/mL5.2 ± 1.85.0 ± 1.75.4 ± 1.8 .2507
ALT, IU/mL121 ± 96.7125.8 ± 81.6115.3 ± 112.7.6149
FIB-41.7 ± 0.71.7 ± 0.71.6 ± 0.7.2976
Total (n = 94)Group A (n = 51)Group B (n = 43)P
(Group A vs Group B)
HBsAg, log10 IU/mL3.7 ± 0.63.7 ± 0.63.6 ± 0.7.2285
HBeAg, log10 PEIU/mL2.0 ± 1.01.9 ± 1.02.1 ± 0.9.2121
HBV DNA, log 10 cps/mL5.2 ± 1.85.0 ± 1.75.4 ± 1.8 .2507
ALT, IU/mL121 ± 96.7125.8 ± 81.6115.3 ± 112.7.6149
FIB-41.7 ± 0.71.7 ± 0.71.6 ± 0.7.2976

Data are presented as mean ± SD.

Abbreviations: ALT, alanine aminotransferase; FIB-4, Fibrosis-4; HBV, hepatitis B virus.

Table 2.

Characteristics of Patients at Week 24

Total (n = 94)Group A (n = 51)Group B (n = 43)P
(Group A vs Group B)
HBsAg, log10 IU/mL3.7 ± 0.63.7 ± 0.63.6 ± 0.7.2285
HBeAg, log10 PEIU/mL2.0 ± 1.01.9 ± 1.02.1 ± 0.9.2121
HBV DNA, log 10 cps/mL5.2 ± 1.85.0 ± 1.75.4 ± 1.8 .2507
ALT, IU/mL121 ± 96.7125.8 ± 81.6115.3 ± 112.7.6149
FIB-41.7 ± 0.71.7 ± 0.71.6 ± 0.7.2976
Total (n = 94)Group A (n = 51)Group B (n = 43)P
(Group A vs Group B)
HBsAg, log10 IU/mL3.7 ± 0.63.7 ± 0.63.6 ± 0.7.2285
HBeAg, log10 PEIU/mL2.0 ± 1.01.9 ± 1.02.1 ± 0.9.2121
HBV DNA, log 10 cps/mL5.2 ± 1.85.0 ± 1.75.4 ± 1.8 .2507
ALT, IU/mL121 ± 96.7125.8 ± 81.6115.3 ± 112.7.6149
FIB-41.7 ± 0.71.7 ± 0.71.6 ± 0.7.2976

Data are presented as mean ± SD.

Abbreviations: ALT, alanine aminotransferase; FIB-4, Fibrosis-4; HBV, hepatitis B virus.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close